BRG
MIST icon

Bay Rivers Group’s Milestone Pharmaceuticals MIST Stock Holding History

Bay Rivers Group’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.5K Buy
46,633
+16,722
+56% +$26.7K 0.02% 125
2026
Q1 		$35.6K Buy
29,911
+1,050
+4% +$1.84K 0.01% 108
2025
Q4 		$58.3K Buy
28,861
+12,170
+73% +$26.2K 0.02% 96
2025
Q3 		$33.4K Buy
16,691
+2,370
+17% +$4.17K 0.01% 91
2025
Q2 		$27.8K Buy
+14,321
New +$19.1K 0.01% 89

Other funds holding MIST

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OE
October Effect Virginia Beach, Virginia $106M AUM 85.28% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
SC
Stephenson & Company San Clemente, California $213M AUM 15.03% 1-Year Est. Return
TFG
Taylor Financial Group Roanoke, Virginia $182M AUM 21.76% 1-Year Est. Return
VR
Vision Retirement Ridgewood, New Jersey $414M AUM
BWG
Beta Wealth Group San Diego, California $267M AUM 18.9% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IIA
Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return

Bay Rivers Group's MIST Position: Q2 2026 in Review

Bay Rivers Group increased its Milestone Pharmaceuticals (MIST) stake by 56% in Q2 2026, buying an estimated $26.7K and bringing the position to 46,633 shares worth $62.5K. The position accounts for 0.02% of the portfolio, ranked #125.

Bay Rivers Group first reported a position in MIST in Q2 2025 and has held it in 5 quarters since. 13 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Bay Rivers Group held 46,633 shares of Milestone Pharmaceuticals worth $62.5K as of Q2 2026.
  • Bay Rivers Group bought 16,722 Milestone Pharmaceuticals shares in Q2 2026, an estimated $26.7K.
  • Milestone Pharmaceuticals made up 0.02% of Bay Rivers Group's portfolio in Q2 2026, its #125 holding.
  • Bay Rivers Group first reported a position in Milestone Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 13 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Bay Rivers Group's 13F filing for Q2 2026, filed 9 Jul 2026.